ESLA

Business Context and Reporting Period

Estrella Immunopharma, Inc. (ESLA) is a clinical-stage biopharmaceutical company developing T-cell therapies (EB103 and EB104) targeting CD19 and CD22 for blood cancers and solid tumors. The company operates as a single segment and is classified as an emerging growth company and smaller reporting company. This Form 10-Q covers the quarterly period ended March 31, 2025. The company changed its fiscal year-end from June 30 to December 31 effective November 25, 2024.

Key Financial Metrics

Material Changes vs. Prior Period

• Significant Increase in Operating Loss: Net loss increased by approximately $1.6 million (346%) compared to Q1 2024, driven primarily by the acceleration of clinical trial activities.
• R&D Expense Surge: Research and development expenses jumped from $25,000 to $1.41 million. This increase is attributed to milestone fees and service charges related to the STARLIGHT-1 Phase I/II clinical trial for product candidate EB103, managed by related party Eureka Therapeutics.
• Cash Position Decline: Cash and cash equivalents decreased by approximately $495,000 during the quarter, leaving the company with roughly $0.4 million in liquidity.
• Related Party Liabilities: Accrued liabilities to related parties increased significantly to $4.14 million (from $2.79 million) due to accrued dosing milestones for the clinical trial.
• Stock-Based Compensation: The company recorded $159,095 in stock-based compensation expense in Q1 2025, compared to $0 in Q1 2024, following option grants in October 2024.

Guidance, Outlook, Risks, and Contingencies

• Liquidity and Going Concern: Management believes it has sufficient funds to meet working capital requirements for at least the next 12 months, relying on cash on hand and the ability to raise funds via an Equity Line Agreement with White Lion (up to $50 million). However, the company has a history of losses and expects negative cash flows to continue until regulatory approval and commercialization.
• Clinical Trial Progress: The STARLIGHT-1 trial is ongoing. As of March 31, 2025, three patients had been dosed. In April 2025 (subsequent event), a fourth patient was dosed and a second site activated, triggering an additional $1.875 million in accrued liabilities.
• Nasdaq Listing Compliance: The company received notice on April 30, 2025, of non-compliance with Nasdaq Listing Rule 5550(a)(2) due to the common stock closing bid price falling below $1.00 for 30 consecutive business days. The company has an initial 180-day compliance period ending October 27, 2025, to regain compliance.
• Internal Control Weakness: Management identified a material weakness in internal control over financial reporting due to a lack of qualified full-time personnel with appropriate accounting knowledge to address complex U.S. GAAP issues. Remediation efforts are underway.
• Related Party Dependence: The company relies heavily on Eureka Therapeutics for manufacturing, clinical trial services, and technical assistance. Termination of these agreements could materially adversely affect operations.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $0.4 million cash balance against the $33 million total potential fees under the Statement of Work with Eureka and the $4.1 million already accrued.
• Financing Capability: Assess the likelihood of utilizing the $50 million Equity Line with White Lion, noting the 20% issuance cap without shareholder approval and the current low stock price.
• Nasdaq Delisting Risk: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement before the October 27, 2025 deadline to avoid delisting.
• Related Party Transactions: Review the terms of the Statement of Work with Eureka, specifically the milestone triggers and the total potential liability of $33 million.
• Internal Controls: Evaluate the progress of remediation for the material weakness in financial reporting controls.